Lepelley M, Allouchery M, Long J, Boucherle D, Ranchoup Y, Le Marc’Hadour F, Villier C, Sturm N

Language: English
References: 30
Page: 1067-1071
PDF size: 308.70 Kb.

ABSTRACT

Trastuzumab is a monoclonal antibody targeted against the Human Epidermal Growth Factor Receptor 2 (HER2) overexpressed in some breast cancer. This targeted therapy significantly improves the prognosis of these cancers. Recently an anti-HER2 antibodydrug conjugate was shaped in order to facilitate the targeted delivery of potent cytotoxic drug to cancer cells and to reduce resistance. This formulation, called trastuzumab emtansine (T-DM1), consists of the monoclonal antibody trastuzumab linked to a cytotoxic drug (a derivative of maytansine) via a chemical linker. Little is known about adverse reactions due to this new formulation. Herein we described the case of a woman suffering from a HER2-positive breast cancer, treated with trastuzumab for 30 months followed by T-DM1 monotherapy. After 12 months of T-DM1 treatment, a nodular regenerative hyperplasia confirmed by liver biopsy occurred. T-DM1 was stopped and medical imagery showed a resolution of the nodular regenerative hyperplasia. Unfortunately, hepatic metastasis progressed. Few cases of nodular regenerative hyperplasia induced by T-DM1 have been described so far. Further studies are needed to explore pathogenesis of nodular regenerative hyperplasia with this new antibody-drug conjugate treatment.

REFERENCES

1. Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL. HER-2/neu oncogene protein and prognosis in breast cancer. J. Clin. Oncol. Off J Am Soc Clin Oncol 1989; 7: 1120-8.

2. Gusterson BA1, Gelber RD, Goldhirsch A, Price KN, Säve- Söderborgh J, Anbazhagan R, Styles J, et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol Off J Am Soc Clin Oncol 1992; 10: 1049-56.

3. Chia SK, Speers CH, D’yachkova Y, Kang A, Malfair-Taylor S, Barnett J, Coldman A, et al. The impact of new chemotherapeutic and hormone agents on survival in a populationbased cohort of women with metastatic breast cancer. Cancer 2007; 110: 973-9.

4. Gennari A, Conte P, Rosso R, Orlandini C, Bruzzi P. Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer 2005; 104: 1742-50.

5. Maciá ES, Rodríguez LA, Pons SV, Martínez BN, Guillén PC, Carrato MA. A patient with breast cancer with hepatic metastases and a complete response to herceptin as monotherapy. Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex 2006; 8: 761-3.

6. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol Off J Am Soc Clin Oncol 1999; 17: 2639-48.

7. Luque-Cabal M, García-Teijido P, Fernández-Pérez Y, Sánchez-Lorenzo L, Palacio-Vázquez I. Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It. Clin Med Insights Oncol 2016; 10: 21-30.

8. Ozkavruk EN, Aktas S, Ozgur H, Ercetin P, Kupelioglu A. The role of p95HER2 in trastuzumab resistance in breast cancer. J BUON Off J Balk Union Oncol 2016; 21: 382-9.

9. Thomas A, Teicher BA, Hassan R. Antibody-drug conjugates for cancer therapy. Lancet Oncol 2016); 17: e254-262.

10. Recondo G, et al. Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine. Cancer Manag Res 2016; 8: 57-65.

11. Barok M, Joensuu H, Isola J. Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res. BCR 2014; 16: 209.

12. Watanabe J, et al. Safety Evaluation of Trastuzumab Emtansine in Japanese Patients with HER2-Positive Advanced Breast Cancer. In Vivo 2017; 31: 493-500.

13. Yan H, Endo Y, Shen Y, Rotstein D, Dokmanovic M, Mohan N, Mukhopadhyay P, et al. Ado-Trastuzumab Emtansine Targets Hepatocytes Via Human Epidermal Growth Factor Receptor 2 to Induce Hepatotoxicity. Mol Cancer Ther 2016; 15: 480-90.

14. Wanless IR. Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules. Hepatol Baltim Md 1990; 11: 787-97.

15. Wanless I R, Godwin TA, Allen F, Feder A. Nodular regenerative hyperplasia of the liver in hematologic disorders: a possible response to obliterative portal venopathy. A morphometric study of nine cases with an hypothesis on the pathogenesis. Medicine (Baltimore) 1980; 59: 367-79.

16. Shimamatsu K, Wanless IR. Role of ischemia in causing apoptosis, atrophy, and nodular hyperplasia in human liver. Hepatol Baltim Md 1997; 26: 343-50.

17. Ghabril M, Vuppalanchi R. Drug-induced nodular regenerative hyperplasia. Semin Liver Dis 201434; 240-5.

18. Diéras V, Harbeck N, Budd GT, Greenson JK, Guardino AE, Samant M, Chernyukhin N, et al. Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis. J Clin Oncol Off J Am Soc Clin Oncol 2014; 32: 2750-7.

19. Force J, Saxena R, Schneider BP, Storniolo AM, Sledge GW Jr, Chalasani N, Vuppalanchi R, et al. Nodular Regenerative Hyperplasia After Treatment With Trastuzumab Emtansine. J Clin Oncol Off J Am Soc Clin Oncol 2016; 34: e9-12.

20. Williams JP, Handler HL. Antibody-targeted chemotherapy for the treatment of relapsed acute myeloid leukemia. Am J Manag Care 2000; 6: S975-985.

21. Magwood-Golston JS, Kessler S, Bennett CL. Evaluation of gemtuzumab ozogamycin associated sinusoidal obstructive syndrome: Findings from an academic pharmacovigilance program review and a pharmaceutical sponsored registry. Leuk Res 2016; 44: 61-4.

22. Fan CQ, Crawford JM. Sinusoidal Obstruction Syndrome (Hepatic Veno-Occlusive Disease). J Clin Exp Hepatol 2014; 4: 332-46.

23. Rajvanshi P, Shulman HM, Sievers EL, McDonald GB. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood 2002; 99: 2310-14.

24. Shen BQ, Bumbaca D, Saad O, Yue Q, Pastuskovas CV, Khojasteh SC, Tibbitts J, et al. Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (TDM1): an emphasis on preclinical and clinical catabolism. Curr Drug Metab 2012; 13: 901-910.

25. Widdison W, Wilhelm S, Veale K, Costoplus J, Jones G, Audette C, Leece B, et al. Metabolites of antibody-maytansinoid conjugates: characteristics and in vitro potencies. Mol Pharm 2015; 12: 1762-73.

26. Erickson HK, Lambert JM. ADME of antibody-maytansinoid conjugates. AAPS J 2012; 14: 799-805.

27. Sun X, Widdison W, Mayo M, Wilhelm S, Leece B, Chari R, Singh R, et al. Design of antibody-maytansinoid conjugates allows for efficient detoxification via liver metabolism. Bioconjug Chem 2011; 22: 728-35.

28. Eagan RT, Ingle JN, Rubin J, Frytak S, Moertel CG. Early clinical study of an intermittent schedule for maytansine (NSC- 153858): brief communication. J Natl Cancer Inst. 1978; 60: 93-6.

29. Junutula JR, Flagella KM, Graham RA, Parsons KL, Ha E, Raab H, Bhakta S, Nguyen T, et al. Engineered thio-trastuzumab- DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res 2010; 16: 4769-78.

30. Lewis PGD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blättler WA, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008; 68: 9280-90.